Active
SME

Goldline Pharmaceutical Ltd

Goldline Pharmaceutical Ltd IPO opens on 12 May 2026 and closes on 14 May 2026, with a price band of ₹41–₹43 per share. The IPO has a lot size of 3000 shares, requiring a minimum investment of ₹2,58,000. The issue size is ₹11.61 crore, and the shares are expected to list on 19 May 2026.

Goldline Pharmaceutical Ltd IPO Details

Listing Date

19 May 2026

Bid Price

₹41 - ₹43

Lot Size

3000 Shares

Minimum Investment

₹2,58,000 / 2 Lots

Issue Size

₹11.61 Cr

Key Dates to Track

    Here are the important dates you need to know in order to participate in this IPO

tick

Offer Start Date

12th May

tick

Offer End Date

14th May

tick

Allotment Date

15th May

tick

Refund Initiation

18th May

tick

Demat Transfer

18th May

tick

Listing Date

19th May

Goldline Pharmaceutical Ltd Shareholding Pattern

  Pre-Issue Post-Issue
Promoter Group 79.7% 57.3%
Public Group 20.3% 42.7%

Goldline Pharmaceutical Ltd IPO Reservation

QIB Shares Offered 5,40,000 (20%)
NII (HNI) Shares Offered 3,90,000 (14.44%)
Retail Shares Offered 9,00,000 (33.33%)
Anchor Investor Shares Offered 7,32,000 (27.11%)
Total Shares Offered 27,00,000
Total Shares With Anchor Investor 27,00,000

Goldline Pharmaceutical Ltd IPO Lot Size

Application Lots Shares Amount
Retail (Min) 2 6,000 ₹2,58,000
Retail (Max) 2 6,000 ₹2,58,000
S HNI (Min) 3 9,000 ₹3,87,000
S HNI (Max) 7 21,000 ₹9,03,000
B HNI (MIN) 8 24,000 ₹10,32,000

Goldline Pharmaceutical Ltd IPO Anchor Portion Size

Bid Date May 11, 2026

Goldline Pharmaceutical Ltd IPO registrar

Bigshare Services Pvt Ltd
Phone Number +91 22 6263 8200
Email Id ipo@bigshareonline.com
Website www.bigshareonline.com

Goldline Pharmaceutical Ltd IPO Lead Manager

1. Cumulative Capital Private Limited

Goldline Pharmaceutical Ltd Financial Information

March 31, 2025 March 31, 2024 March 31, 2023
Net Worth ₹10.35 Cr ₹7.87 Cr ₹5.89 Cr
Reserves and Surplus ₹1.65 Cr ₹3.76 Cr ₹2.08 Cr
Total Borrowing ₹11.03 Cr ₹11.13 Cr ₹10.83 Cr

Strength of Goldline Pharmaceutical Ltd

  • Experienced promoters and management team with industry knowledge and a track record.
  • Asset-light business model and competitive products.
  • Scalable Business Model.
  • Wide and diverse range of product offerings.
  • Strong Supplier and Vendor Relationships.
  • Established Distribution Network.

Risks Involved

  • Its rely entirely on third-party contract manufacturers for the manufacturing of the company pharmaceutical products, and any failure or inability of such manufacturers to meet quality, regulatory, delivery or capacity requirements could adversely affect its business, results of operations and financial condition.
  • The Company has experienced delays in filing e-forms with the Registrar of Companies (RoC) in the past, resulting in the payment of late fees. Further, there have also been instances of erroneous filings made by the Company, in the past. While no regulatory actions or penalties has been imposed to date except below mentioned, there is no assurance that such actions will not be levied in the future. The Company cannot guarantee that similar delays will not occur in the future, and if regulatory authorities impose penalties or take punitive actions against the Company or its directors/officers, it could negatively affect the Company's business and financial condition.
  • The company commercial success is largely dependent upon its ability to analyses the market of new pharmaceutical products, failure of which may has an adverse impact on its revenue and profitability.
  • There has been instances of delays in payment of statutory dues, i.e. GST by the Company. In case of any delay in payment of statutory due in future by the Company, the Regulatory Authorities may impose monetary penalties on it or take certain punitive actions against the Company in relation to the same which may has adverse impact on its business, financial condition and results of operations.
  • Its depend on the company distributors for a significant portion of its revenue, and any decrease in revenues or sales from any one of the company key intermediaries may adversely affect its business and results of operations. the Company has a distribution network of 8 distributors and is dependent on these distributors for a significant portion of its revenue. If the company unable to maintain its relationship with such customers or if there is a reduction in their demand for the company products, its business, results of operations and financial condition will be materially and adversely affected.
  • There are outstanding mitigations involving the Company, Promoters, Directors, Key Managerial Personnel, Senior Management and Group Companies, if determined adversely, may adversely affect its business and financial condition.
  • The company Promoter Group entities Numerius Healthcare Private Limited, Nucleage Lifescience Private Limited and Nucleage Pharma Solutions Private Limited has conflicts of interest as they are engaged in similar business and may compete with it.
  • Its derive a significant portion of the company revenue from certain of its products. If sales volume or price of such products declines in the future, or if the company unable to sell such products for any reason, its business, financial condition, cash flows and results of operations could be adversely affected.
  • The company operate in limited geographies for a significant portion of its revenue and also depends on limited number of customers for the company revenue from operations.
  • The Company had negative cash flows in the past years, details of which are given below. Sustained negative cash flow could impact its growth and business.
stock
Invest in IPOs with ease

Sign-in to invest with your demat account, or set up a new demat account for free

Explore Other IPOs

  • Current IPOs
  • Upcoming IPOs
  • Closed IPOs
  • IPO Performance
  • All
  • MainBoard
  • SME
Goldline Pharmaceutical Limited IPO
Bidding Period
12th May 2026 - 5th May 2026
Price Range
₹41.0 - 43.0
IPO Size
₹11,61,00,000
RFBL Flexi Pack Limited IPO
Bidding Period
12th May 2026 - 5th May 2026
Price Range
₹47.0 - 50.0
IPO Size
₹35,33,00,000
Aarvee Engineering Consultants Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Aastha Spintex Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Absolute Project India Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
AceVector Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Adroit Industries India Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advanced SysTek Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advanta Enterprises Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advit Jewels Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Aggcon Equipments International Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Agilus Diagnostics Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Airox Technologies Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Ajay Poly Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Alcobrew Distilleries India Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Allchem Lifescience Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Allied Engineering Works Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Alpine Texworld Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Annu Projects Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
AOne Steels India Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
NO ACTIVE IPO HERE
  • All
  • MainBoard
  • SME
BAGMANE PRIME OFFICE REIT IPO
Bidding Period
5th May 2026 - 5th May 2026
Price Range
₹95.0 - 100.0
IPO Size
₹34,05,00,00,000
RECODE STUDIOS LIMITED IPO
Bidding Period
5th May 2026 - 5th May 2026
Price Range
₹150.0 - 158.0
IPO Size
₹45,00,00,000
VALUE 360 COMMUNICATIONS LIMITED IPO
Bidding Period
4th May 2026 - 5th May 2026
Price Range
₹95.0 - 98.0
IPO Size
₹42,00,00,000
ONEMI TECHNOLOGY SOLUTIONS LIMITED IPO
Bidding Period
30th Apr 2026 - 5th May 2026
Price Range
₹162.0 - 171.0
IPO Size
₹9,26,00,00,000
AMBA AUTO SALES AND SERVICES LIMITED IPO
Bidding Period
27th Apr 2026 - 4th Apr 2026
Price Range
₹130.0 - 135.0
IPO Size
₹65,00,00,000
ADISOFT TECHNOLOGIES LIMITED IPO
Bidding Period
23rd Apr 2026 - 4th Apr 2026
Price Range
₹163.0 - 172.0
IPO Size
₹74,00,00,000
CITIUS TRANSNET INVESTMENT TRUST IPO
Bidding Period
17th Apr 2026 - 4th Apr 2026
Price Range
₹99.0 - 100.0
IPO Size
₹11,05,00,00,000
MEHUL TELECOM LIMITED IPO
Bidding Period
17th Apr 2026 - 4th Apr 2026
Price Range
₹96.0 - 98.0
IPO Size
₹28,00,00,000
OM POWER TRANSMISSION LIMITED IPO
Bidding Period
9th Apr 2026 - 4th Apr 2026
Price Range
₹166.0 - 175.0
IPO Size
₹1,50,00,00,000
SAFETY CONTROLS AND DEVICES LIMITED IPO
Bidding Period
6th Apr 2026 - 4th Apr 2026
Price Range
₹75.0 - 80.0
IPO Size
₹48,00,00,000
EMIAC TECHNOLOGIES LIMITED IPO
Bidding Period
27th Mar 2026 - 4th Apr 2026
Price Range
₹93.0 - 98.0
IPO Size
₹32,00,00,000
VIVID ELECTROMECH LIMITED IPO
Bidding Period
25th Mar 2026 - 3rd Mar 2026
Price Range
₹528.0 - 555.0
IPO Size
₹1,31,00,00,000
HIGHNESS MICROELECTRONICS LIMITED IPO
Bidding Period
24th Mar 2026 - 3rd Mar 2026
Price Range
₹114.0 - 120.0
IPO Size
₹22,00,00,000
AMIR CHAND JAGDISH KUMAR EXPORTS LIMITED IPO
Bidding Period
24th Mar 2026 - 3rd Mar 2026
Price Range
₹201.0 - 212.0
IPO Size
₹4,40,00,00,000
SAI PARENTERAL'S LIMITED IPO
Bidding Period
24th Mar 2026 - 3rd Mar 2026
Price Range
₹372.0 - 392.0
IPO Size
₹4,09,00,00,000
POWERICA LIMITED IPO
Bidding Period
24th Mar 2026 - 3rd Mar 2026
Price Range
₹375.0 - 395.0
IPO Size
₹11,00,00,00,000
TIPCO ENGINEERING INDIA LIMITED IPO
Bidding Period
23rd Mar 2026 - 3rd Mar 2026
Price Range
₹84.0 - 89.0
IPO Size
₹61,00,00,000
SPECIALITY MEDICINES LIMITED IPO
Bidding Period
20th Mar 2026 - 3rd Mar 2026
Price Range
₹117.0 - 124.0
IPO Size
₹29,00,00,000
CENTRAL MINE PLANNING AND DESIGN INSTITUTE LIMITED IPO
Bidding Period
20th Mar 2026 - 3rd Mar 2026
Price Range
₹163.0 - 172.0
IPO Size
₹18,42,00,00,000
NOVUS LOYALTY LIMITED IPO
Bidding Period
17th Mar 2026 - 3rd Mar 2026
Price Range
₹139.0 - 146.0
IPO Size
₹60,00,00,000
  • All
  • MainBoard
  • SME
GSP CROP SCIENCE LIMITED IPO
Issue Prize
320.00
Listing Day Close
356.10(11.25%)
INNOVISION LIMITED IPO
Issue Prize
519.00
Listing Day Close
372.80(-28.13%)
RAAJMARG INFRA INVESTMENT TRUST IPO
Issue Prize
100.00
Listing Day Close
106.83(7.00%)
APSIS AEROCOM LIMITED IPO
Issue Prize
110.00
Listing Day Close
160.65(46.36%)
RAJPUTANA STAINLESS LIMITED IPO
Issue Prize
122.00
Listing Day Close
112.90(-7.38%)
SRINIBAS PRADHAN CONSTRUCTIONS LIMITED IPO
Issue Prize
98.00
Listing Day Close
104.40(6.12%)
ELFIN AGRO INDIA LIMITED IPO
Issue Prize
47.00
Listing Day Close
47.60(2.13%)
SEDEMAC MECHATRONICS LIMITED IPO
Issue Prize
1352.00
Listing Day Close
1452.10(7.40%)
ACETECH ECOMMERCE LIMITED IPO
Issue Prize
112.00
Listing Day Close
117.60(5.36%)
STRIDERS IMPEX LIMITED IPO
Issue Prize
72.00
Listing Day Close
66.50(-6.94%)
YAAP DIGITAL LIMITED IPO
Issue Prize
145.00
Listing Day Close
133.35(-8.28%)
OMNITECH ENGINEERING LIMITED IPO
Issue Prize
227.00
Listing Day Close
205.15(-9.69%)
PNGS REVA DIAMOND JEWELLERY LIMITED IPO
Issue Prize
386.00
Listing Day Close
413.95(7.25%)
KIAASA RETAIL LIMITED IPO
Issue Prize
127.00
Listing Day Close
116.85(-7.87%)
MOBILISE APP LAB LIMITED IPO
Issue Prize
80.00
Listing Day Close
67.30(-16.25%)
ACCORD TRANSFORMER AND SWITCHGEAR LIMITED IPO
Issue Prize
46.00
Listing Day Close
52.50(15.22%)
CLEAN MAX ENVIRO ENERGY SOLUTIONS LIMITED IPO
Issue Prize
1053.00
Listing Day Close
867.90(-17.57%)
SHREE RAM TWISTEX LIMITED IPO
Issue Prize
104.00
Listing Day Close
73.45(-29.81%)
GAUDIUM IVF AND WOMEN HEALTH LIMITED IPO
Issue Prize
79.00
Listing Day Close
80.48(1.27%)
MANILAM INDUSTRIES INDIA LIMITED IPO
Issue Prize
69.00
Listing Day Close
52.45(-24.64%)

Frequently Asked Questions

What is Goldline Pharmaceutical Ltd IPO?

Answer Field

Goldline Pharmaceutical Ltd IPO is a SME IPO of 27,00,000 equity shares of a face value of ₹10 aggregating up to ₹11.61 Crores. The issue is priced at ₹41 to ₹43 per share. The minimum order quantity is 3000 Shares. The IPO opens on May 12, 2026, and closes on May 14, 2026. Bigshare Services Pvt Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE-SME.

When Goldline Pharmaceutical Ltd IPO will open?

Answer Field

The Goldline Pharmaceutical Ltd IPO opens on May 12, 2026 and closes on May 14, 2026.

What is the lot size of Goldline Pharmaceutical Ltd?

Answer Field

Goldline Pharmaceutical Ltd lot size is 3000 shares, and the minimum amount required is ₹2,58,000.

How to apply for Goldline Pharmaceutical Ltd IPO?

Answer Field

You can apply in Goldline Pharmaceutical Ltd IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. To apply for an IPO:

  • Login to Bajaj Broking account App/Website & click on IPO
  • Enter the number of lots and price at which you wish to apply.
  • Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.
  • You will receive a mandate notification to block funds in your UPI app.
  • Approve the mandate request on your UPI and funds will be blocked.

When is Goldline Pharmaceutical Ltd IPO allotment?

Answer Field

The finalization of Basis of Allotment for Goldline Pharmaceutical Ltd IPO will be done on May 15, 2026, and the allotted shares will be credited to your demat account by May 18, 2026.

When is Goldline Pharmaceutical Ltd IPO listing date?

Answer Field

The Goldline Pharmaceutical Ltd listing date is May 19, 2026.

Who is the registrar of Goldline Pharmaceutical Ltd IPO?

Answer Field

The registrar of Goldline Pharmaceutical Ltd IPO is Bigshare Services Pvt Ltd

Which company is the book-running lead manager of the IPO?

Answer Field

Cumulative Capital Private Limited will be the book-running lead manager of this IPO.

What is the fresh issue of Goldline Pharmaceutical Ltd IPO?

Answer Field

The fresh issue size is ₹11.61 Crores equity shares.

What minimum lot size can retail subscribers subscribe to Goldline Pharmaceutical Ltd?

Answer Field

Retail investors can subscribe to a minimum of one lot, 3000 shares and ₹2,58,000 amount.

How can I approve the UPI mandate request for Goldline Pharmaceutical Ltd IPO?

Answer Field

To apply for Goldline Pharmaceutical Ltd IPO, you need to log in to your demat account to complete the bidding process. Then, approve the payment mandate on your UPI app.

What is the price range of Goldline Pharmaceutical Ltd?

Answer Field

The price of each Goldline Pharmaceutical Ltd share will be ranging in between ₹41 to ₹43 per share.

What is the cut-off time for the UPI mandate for Goldline Pharmaceutical Ltd IPO?

Answer Field

The cut-off time for the UPI mandate confirmation is 5:00 PM, May 14, 2026.

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|